JP2015525754A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015525754A5 JP2015525754A5 JP2015521001A JP2015521001A JP2015525754A5 JP 2015525754 A5 JP2015525754 A5 JP 2015525754A5 JP 2015521001 A JP2015521001 A JP 2015521001A JP 2015521001 A JP2015521001 A JP 2015521001A JP 2015525754 A5 JP2015525754 A5 JP 2015525754A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- liquid aqueous
- aqueous pharmaceutical
- ylethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 31
- 239000007788 liquid Substances 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 8
- ODIUNTQOXRXOIV-UHFFFAOYSA-N 1-[6-[[6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea Chemical compound C1=CC(F)=CC=C1C1=NN2C(SC=3C=C4SC(NC(=O)NCCN5CCOCC5)=NC4=CC=3)=NN=C2C=C1 ODIUNTQOXRXOIV-UHFFFAOYSA-N 0.000 claims 7
- 229920000858 Cyclodextrin Polymers 0.000 claims 7
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 4
- -1 6-{[6- (4-fluorophenyl) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl} -1,3-benzothiazol-2-yl Chemical group 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 101150105382 MET gene Proteins 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 208000037844 advanced solid tumor Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305840 | 2012-07-12 | ||
| EP12305840.6 | 2012-07-12 | ||
| PCT/EP2013/064741 WO2014009500A1 (en) | 2012-07-12 | 2013-07-11 | Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015525754A JP2015525754A (ja) | 2015-09-07 |
| JP2015525754A5 true JP2015525754A5 (enExample) | 2016-08-12 |
Family
ID=48782350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521001A Pending JP2015525754A (ja) | 2012-07-12 | 2013-07-11 | 化合物１−（６−｛［６−（４−フルオロフェニル）［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン−３−イル］スルファニル｝−１，３−ベンゾチアゾール−２−イル）−３−（２−モルホリン−４−イルエチル）尿素を含む抗腫瘍組成物 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20150119391A1 (enExample) |
| EP (1) | EP2872119A1 (enExample) |
| JP (1) | JP2015525754A (enExample) |
| KR (1) | KR20150030761A (enExample) |
| CN (1) | CN104470500A (enExample) |
| AR (1) | AR091727A1 (enExample) |
| AU (1) | AU2013288676A1 (enExample) |
| BR (1) | BR112015000497A2 (enExample) |
| CA (1) | CA2878500A1 (enExample) |
| CL (1) | CL2015000074A1 (enExample) |
| CO (1) | CO7160069A2 (enExample) |
| CR (1) | CR20150005A (enExample) |
| EA (1) | EA201590199A1 (enExample) |
| HK (1) | HK1209642A1 (enExample) |
| IL (1) | IL236662A0 (enExample) |
| IN (1) | IN2015KN00075A (enExample) |
| MA (1) | MA37753B1 (enExample) |
| MX (1) | MX2015000532A (enExample) |
| PH (1) | PH12015500060A1 (enExample) |
| SG (1) | SG11201500123XA (enExample) |
| TN (1) | TN2015000011A1 (enExample) |
| TW (1) | TW201402121A (enExample) |
| UY (1) | UY34909A (enExample) |
| WO (1) | WO2014009500A1 (enExample) |
| ZA (1) | ZA201500129B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240096905A (ko) * | 2021-12-15 | 2024-06-26 | 신라젠(주) | 변형된 베타-사이클로덱스트린을 포함하는 약제학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711643D0 (en) * | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| FR2817750B1 (fr) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Composition pharmaceutique de dronedarone pour administration parenterale |
| EP1594434B1 (en) * | 2003-01-14 | 2016-09-07 | Yeda Research and Development Co. | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| PA8792501A1 (es) * | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| AR071354A1 (es) * | 2008-02-28 | 2010-06-16 | Takeda Pharmaceutical | Composicion farmaceutica que comprende derivados de 5-(3-(etilsulfonil)fenil)-3,8-dimetil-n-(1-metilpiperidin-4-il)-9h-pirido [2,3-b]indol-7-carboxamida y una b ciclodextrina para mejorar su solubilidad |
| CN101444510B (zh) * | 2008-12-31 | 2011-03-09 | 南京卡文迪许生物工程技术有限公司 | 含有伏立康唑的药物制剂及其制备方法 |
| FR2941951B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
-
2013
- 2013-07-11 EA EA201590199A patent/EA201590199A1/ru unknown
- 2013-07-11 JP JP2015521001A patent/JP2015525754A/ja active Pending
- 2013-07-11 WO PCT/EP2013/064741 patent/WO2014009500A1/en not_active Ceased
- 2013-07-11 SG SG11201500123XA patent/SG11201500123XA/en unknown
- 2013-07-11 AU AU2013288676A patent/AU2013288676A1/en not_active Abandoned
- 2013-07-11 HK HK15110497.0A patent/HK1209642A1/xx unknown
- 2013-07-11 CA CA 2878500 patent/CA2878500A1/en not_active Abandoned
- 2013-07-11 MX MX2015000532A patent/MX2015000532A/es unknown
- 2013-07-11 AR ARP130102458 patent/AR091727A1/es unknown
- 2013-07-11 TW TW102124952A patent/TW201402121A/zh unknown
- 2013-07-11 BR BR112015000497A patent/BR112015000497A2/pt not_active IP Right Cessation
- 2013-07-11 IN IN75KON2015 patent/IN2015KN00075A/en unknown
- 2013-07-11 KR KR20157003404A patent/KR20150030761A/ko not_active Withdrawn
- 2013-07-11 CN CN201380037070.8A patent/CN104470500A/zh active Pending
- 2013-07-11 MA MA37753A patent/MA37753B1/fr unknown
- 2013-07-11 EP EP13735312.4A patent/EP2872119A1/en not_active Withdrawn
- 2013-07-12 UY UY34909A patent/UY34909A/es not_active Application Discontinuation
-
2015
- 2015-01-07 CR CR20150005A patent/CR20150005A/es unknown
- 2015-01-08 ZA ZA2015/00129A patent/ZA201500129B/en unknown
- 2015-01-08 CO CO15004112A patent/CO7160069A2/es unknown
- 2015-01-08 TN TNP2015000011A patent/TN2015000011A1/fr unknown
- 2015-01-09 PH PH12015500060A patent/PH12015500060A1/en unknown
- 2015-01-09 CL CL2015000074A patent/CL2015000074A1/es unknown
- 2015-01-09 US US14/593,059 patent/US20150119391A1/en not_active Abandoned
- 2015-01-11 IL IL236662A patent/IL236662A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540499A5 (enExample) | ||
| JP6738376B2 (ja) | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 | |
| JP2015536996A5 (enExample) | ||
| RU2015134583A (ru) | Фармацевтические композиции, содержащие доноры нитроксила | |
| JP2016510326A5 (enExample) | ||
| Jin | Arsenic trioxide: an ancient drug revived | |
| JP2015522033A5 (enExample) | ||
| JP2016527202A5 (enExample) | ||
| JP2020523354A5 (enExample) | ||
| JP2019501191A5 (enExample) | ||
| JP2019526559A5 (enExample) | ||
| JP2018516936A5 (enExample) | ||
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| JP2014512355A5 (enExample) | ||
| JP2017534652A5 (enExample) | ||
| Zhang et al. | Self-illuminating in situ hydrogel with immune-adjuvant amplify cerenkov radiation-induced photodynamic therapy | |
| JP2014148552A5 (enExample) | ||
| Jiang et al. | Nanoparticles targeting the adenosine pathway for cancer immunotherapy | |
| RU2018130097A (ru) | Лечение экземы кистей | |
| JP2017516842A5 (enExample) | ||
| AR116922A1 (es) | Formulación basada en ciclodextrina de un inhibidor de bcl-2 | |
| CN105435221B (zh) | 一种针对血管内皮生长因子的人源化抗体的药物组合物 | |
| JP2017516828A5 (enExample) | ||
| RU2014114827A (ru) | Применение 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она для лечения рака у пациентов с умеренной печеночной недостаточностью | |
| EP2035020A2 (en) | Pharmaceutical composition for injectional, particularly targeted local administration |